{"id":"NCT03952039","sponsor":"Celgene","briefTitle":"An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib","officialTitle":"A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-09","primaryCompletion":"2022-12-15","completion":"2025-07-28","firstPosted":"2019-05-16","resultsPosted":"2024-01-30","lastUpdate":"2025-08-28"},"enrollment":202,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Myelofibrosis","Post-Polycythemia Vera","Myelofibrosis"],"interventions":[{"type":"DRUG","name":"FEDRATINIB","otherNames":[]},{"type":"DRUG","name":"Best Available Therapy (BAT)","otherNames":[]}],"arms":[{"label":"Fedratinib 400mg/day","type":"EXPERIMENTAL"},{"label":"Best Available Therapy (BAT)","type":"ACTIVE_COMPARATOR"}],"summary":"A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) and previously treated with ruxolitinib. The primary objective of the study is to evaluate the percentage of subjects with at least 35% spleen volume reduction in the fedratinib and the BAT arms.","primaryOutcome":{"measure":"Spleen Volume Response Rate (RR)","timeFrame":"From Screening to end of Cycle 6 (1 cycle = 28 days), approximately 196 days","effectByArm":[{"arm":"Fedratinib","deltaMin":35.8,"sd":null},{"arm":"Best Available Therapy (BAT)","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":107,"countries":["Australia","Austria","Belgium","China","Czechia","France","Germany","Hungary","Ireland","Italy","Netherlands","Poland","Russia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["39265613"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":72,"n":134},"commonTop":["Anaemia","Diarrhoea","Nausea","Thrombocytopenia","Asthenia"]}}